ArticleNature biomedical engineering2017
A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen.
Article in Nature biomedical engineering, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- MR-based techniques for imaging prostate cancer metabolism: current status and future perspectives.Abdominal radiology (New York) · 2026Review
- Multivalent Antibody-Recruiting Molecules for Targeted Immune-Killing of Carbonic Anhydrase IX-Expressing Cancer Cells.Angewandte Chemie (International ed. in English) · 2026Article
- High mannose content of mesenchymal glioblastoma correlates with hydroxyl proton transfer-weighted (HPTw) MRI as noninvasive biomarker of tumor aggressiveness.Science advances · 2026Article
- Detection of Aggressive Mesenchymal Glioblastoma by Mannose-Weighted CEST MRI.bioRxiv : the preprint server for biology · 2026Article
- Comparison of the efficacy of FITC-conjugated dextran, PEG, and HA as intraoperative navigation materials in pancreatic cancer.RSC advances · 2025Article
- Single-shot multiparametric MRI for separatingTheranostics · 2025Article
- Design Chemical Exchange Saturation Transfer Contrast Agents and Nanocarriers for Imaging Proton ExchangeACS nano · 2024Review
- Construction of Targeting-Peptide-Based Imaging Reagents and Their Application in Bioimaging.Chemical & biomedical imaging · 2024Review
- Article
- A numerical human brain phantom for dynamic glucose-enhanced (DGE) MRI: On the influence of head motion at 3T.Magnetic resonance in medicine · 2023Article
- Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI.Pharmaceutics · 2022Article
- Label-Free Assessment of Mannitol Accumulation Following Osmotic Blood-Brain Barrier Opening Using Chemical Exchange Saturation Transfer Magnetic Resonance Imaging.Pharmaceutics · 2022Article
- Dynamic contrast-enhanced CEST MRI using a low molecular weight dextran.NMR in biomedicine · 2022Article
- Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging.Molecular imaging and biology · 2022Article
- Development of a Nanoscale Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Contrast Agent That Measures pH.ACS nano · 2021Article
- In vitro and in vivo comparison of MRI chemical exchange saturation transfer (CEST) properties between native glucose and 3-O-Methyl-D-glucose in a murine tumor model.NMR in biomedicine · 2021Article
- Article
- Mechanism and quantitative assessment of saturation transfer for water-based detection of the aliphatic protons in carbohydrate polymers.Magnetic resonance in medicine · 2021Article
- Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.Cancer research · 2021Review
- CEST MRI trackable nanoparticle drug delivery systems.Biomedical materials (Bristol, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Safe imaging agents able to render the expression and distribution of cancer receptors, enzymes or other biomarkers would facilitate clinical screening of the disease. Here, we show that diamagnetic dextran particles coordinated to a urea-based targeting ligand for prostate-specific membrane antigen (PSMA) enable targeted magnetic resonance imaging (MRI) of the PSMA receptor. In a xenograft model of prostate cancer, micromolar concentrations of the dextran -ligand probe provided sufficient signal to specifically detect PSMA-expressing tumours via chemical exchange saturation transfer MRI. The dextran-based probe could be detected via the contrast originating from dextran hydroxyl protons, thereby avoiding the need of chemical substitution for radioactive or metallic labelling. Because dextrans are currently used clinically, dextran-based contrast agents may help extend receptor-targeted imaging to clinical MRI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.